rs142967670 — GCDH R88C

GCDH R88C — The Glutaric Acidemia Type 1 Carrier Variant

Glutaryl-CoA dehydrogenase (GCDH) is a mitochondrial enzyme responsible for breaking down three amino acids — lysine, hydroxylysine, and tryptophan — in the final steps of their catabolism. When GCDH fails, its toxic substrates (glutaric acid and 3-hydroxyglutaric acid) accumulate and cause striatal necrosis¹¹ striatal necrosis
destruction of the caudate nucleus and putamen, the brain's movement-coordination centers, triggering a severe movement disorder that resembles dyskinetic cerebral palsy.

The rs142967670 C>T transition creates the p.Arg88Cys substitution — replacing a positively charged arginine with a cysteine at position 88 of the mature protein. Schmiesing et al. 2017²² Schmiesing et al. 2017 showed that R88C disrupts mitochondrial ultrastructure (forming stacked cristae and partially dissolving the outer mitochondrial membrane) and destabilizes the GCDH homotetramer, resulting in complete loss of enzymatic activity. Two copies of this variant cause glutaric acidemia type 1 (GA1), a rare but devastating organic acidemia. One copy produces an unaffected carrier.

The Mechanism

The Arg88 residue sits on the surface of the GCDH subunit interface. Mutating it to cysteine undermines the quaternary assembly of the enzyme into its active homotetramer. The result is twofold: reduced protein stability and aberrant binding to electron transfer flavoprotein beta³³ electron transfer flavoprotein beta
ETFβ, the redox partner that accepts electrons from GCDH during amino acid oxidation. Without functional GCDH, lysine catabolism stalls, and glutarylcarnitine accumulates in blood — the biomarker used in newborn screening. In brain tissue, 3-hydroxyglutaric acid acts as an endogenous neurotoxin that selectively injures the striatum during metabolic stress (febrile illness, fasting, surgery), causing irreversible encephalopathic crises.

The Evidence

GA1 is an autosomal recessive condition: only homozygotes or compound heterozygotes (two different pathogenic GCDH variants) develop disease. Christensen et al. 2004⁴⁴ Christensen et al. 2004 studied 215 GA1 patients and found that more than half had complete absence of GCDH activity, with 34% retaining residual activity up to 5%. No reliable genotype-phenotype correlation for clinical outcome was established — outcome depends primarily on whether an encephalopathic crisis occurs, not which specific mutation is present.

The impact of early detection is stark. Strauss et al. 2020⁵⁵ Strauss et al. 2020 followed 168 GA1 patients across three treatment cohorts spanning 31 years: striatal degeneration occurred in 90% of unscreened patients, 47% of screened patients on protein restriction only, and just 7% of screened patients on specialized lysine-free formula with emergency IV treatment during febrile episodes. No neurological injuries occurred after 19 months of age, identifying the first two years of life as the critical intervention window.

The 2023 international guidelines⁶⁶ The 2023 international guidelines — the third revision led by Boy et al. across European and North American metabolic centers — summarize current best practice: newborn screening via acylcarnitine profiling (glutarylcarnitine elevation), low-lysine diet from diagnosis, L-carnitine supplementation to correct secondary carnitine depletion, and an intensified emergency protocol during any catabolic stress. Dietary restriction can typically be relaxed after age 6, when the brain's striatum is no longer in the vulnerability window.

The R88C allele (c.262C>T) is classified Pathogenic in ClinVar (VCV000189150, 2-star review status, 10 concordant submitters) and listed as OMIM allelic variant 608801.0001. The allele is ultra-rare globally (~5 per 100,000 chromosomes in gnomAD non-Finnish European), consistent with the estimated GA1 birth incidence of 1 in 30,000–100,000 live births across most populations.

Practical Actions

For carriers (one copy, CT genotype): no clinical management of GA1 is required — carriers have one functional GCDH gene and maintain adequate enzyme activity. The practical implication is reproductive: each child of two carriers has a 25% chance of inheriting two pathogenic alleles. Genetic counseling and partner testing are the key actions.

For affected individuals (TT genotype — extremely rare to appear in a standard report): confirmed GA1 requires immediate referral to a metabolic medicine specialist. The cornerstone of treatment is a low-lysine diet (typically using lysine-free amino acid formula), L-carnitine supplementation (50–100 mg/kg/day in children), and an emergency protocol card authorizing IV glucose and L-carnitine during any febrile illness, which is the trigger for the catastrophic striatal crises.

Interactions

GCDH R88C most commonly causes GA1 as a homozygote or in compound heterozygosity with a second pathogenic GCDH variant. Other well-characterized GA1 alleles include R402W (the most common European mutation, ~40% of German alleles), R227P, A421V (the Old Order Amish founder allele), and numerous others across the gene's 11 exons. Compound heterozygotes (R88C on one chromosome, another pathogenic variant on the other) have the same clinical syndrome as R88C homozygotes — the critical variable is whether any residual GCDH activity is preserved.

Secondary carnitine deficiency occurs in all untreated GA1 patients because excess glutaric acid is conjugated to carnitine and excreted as glutarylcarnitine, depleting free carnitine. L-carnitine supplementation directly addresses this mechanism-specific depletion.